COMy

The World Congress on Controversies in Multiple Myeloma (COMy)

[COMy @COMyCongress]

Registration is open for the 13th COMy Congress!

• May 13-16, 2027
• Paris, France + Online

The biggest questions in myeloma, discussed live.

Register on-site at the early bird rate ⬎ https://t.co/bcLyMoLo90

@Mohty_EBMT

[IACH @TheIACH]

🔴 We are Live!

Making sense of treatment options at first relapse

with Joseph Mikhael

Join the webinar →

@jmikhaelmd @Mohty_EBMT

[IACH @TheIACH]

🩺 CAR-T or bispecific? How do we approach early relapse? What comes after BCMA-directed therapy?

Real-life decision making in the era of bispecifics!

Join Mohamad Mohty and Douglas W. Sborov for interactive clinical cases, live polling & panel discussion.

📅 Dec 11 | New Orleans + Virtual

👉 Register: https://t.co/LQCvMSK8mZ

#MultipleMyeloma #IACH

@Mohty_EBMT

[IACH @TheIACH]

→ Tune in to the latest IACH News podcast:

OPTIMUM/MUKnine: Can intensified, risk-adapted therapy overcome high-risk multiple myeloma?
⭣
https://t.co/Cmqp6TOb6R

Click for the abstract ⬎
https://t.co/vzvXQTCSpT

@Mohty_EBMT

[IACH @TheIACH]

👂Hear the latest IACH news in French:

Vers un traitement précoce du myélome multiple indolent ?
⬇️⬇️
https://t.co/ZsfqufDC8P

Click for the abstract👇
https://t.co/xBlAkL04rO

@Mohty_EBMT

[IACH @TheIACH]

🩺 What does the growing use of anti-BCMA bispecific mean for everyday clinical practice?

Find out at the IACH Symposium at ASH 2026.

This focused program will move beyond the clinical trial data to explore the questions that matter in practice — when to use bispecific, how to sequence them, how to manage toxicity and infections, and what to do when patients relapse after BCMA-directed therapy.

📅 December 11 | 07:00–10:00AM CT
💻 In person + virtual

👉 Register:
https://t.co/LQCvMSKGcx

This activity is approved for AMA PRA Category 1 𝘊𝘳𝘦𝘥𝘪𝘵™

#MultipleMyeloma #IACH #Hematology

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

What would Voltaire say about optimizing bridging before CAR-T therapy in multiple myeloma?

My best guess below... thanks @TheIACH @Mohty_EBMT for the invitation!

[IACH @TheIACH]

Join us for the upcoming IACH Multiple Myeloma Masterclass Series:

Making sense of treatment options at first relapse

with Joseph Mikhael

Thursday, November 12
6 pm CET • 12 pm NY

Register now for free👇
https://t.co/gPWszJBTvt

@jmikhaelmd @Mohty_EBMT

[COMy @COMyCongress]

���Now streaming: #COMy2026 ON-DEMAND

Rewatch the sessions everyone’s talking about - exclusively for registered attendees ⤵️

https://t.co/UMgFgBjs67

➡️ Available until July 31st

@Mohty_EBMT

[COMy @COMyCongress]

🎥 The #COMy2026 On-Demand Library now includes highlights from Richard @TheIACH AI Doctor.

Quick summaries and key takeaways from expert discussions in multiple myeloma, all in one place!

👉 Visit the on-demand library:
https://t.co/3AwcxKZIYc

@Mohty_EBMT

[IACH @TheIACH]

🔴 We are Live!

CAR-T: Optimizing Bridging Therapy and Early Response

with Rahul Banerjee

Join the webinar →
https://t.co/U6QtyLzuuM

@RahulBanerjeeMD @Mohty_EBMT

[IACH @TheIACH]

📅 Coming up next month in New Orleans!

Join IACH on December 11 for a focused symposium on anti-BCMA bispecific antibodies in multiple myeloma - from the latest clinical evidence to real-world implementation and practical clinical cases.

Free In person + virtual registration

🔗 https://t.co/LQCvMSKGcx

@Mohty_EBMT @ElenaZamagni @mvmateos @NBahlis

#MultipleMyeloma #Hematology

[IACH @TheIACH]

📣 Join IACH at ASH 2026!

Explore the evolving role of anti-BCMA bispecific antibodies in multiple myeloma with an international expert faculty.

From biology and clinical data to real-world implementation, toxicity management and interactive clinical cases.

📅 December 11 | 07:00–10:00AM CT
📍 In person + virtual

👉 Register now: https://t.co/LQCvMSK8mZ

This activity is approved for AMA PRA Category 1 CreditTM

@Mohty_EBMT @NBahlis @mvmateos @ElenaZamagni

#MultipleMyeloma #IACH

[IACH @TheIACH]

Join us for the upcoming IACH Multiple Myeloma Masterclass Series:

𝗖𝗔𝗥-𝗧: 𝗢𝗽𝘁𝗶𝗺𝗶𝘇𝗶𝗻��� 𝗕𝗿𝗶𝗱𝗴𝗶𝗻𝗴 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗮𝗻𝗱 𝗘𝗮𝗿𝗹𝘆 𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗲

with Rahul Banerjee

Tuesday, November 3
6 pm CET • 12 pm NY

Register now for free👇
https://t.co/U6QtyLzuuM

@RahulBanerjeeMD @Mohty_EBMT

[IACH @TheIACH]

💡 𝘐𝘈𝘊𝘏 𝘞𝘦𝘣𝘪𝘯𝘢𝘳 𝘐𝘯𝘴𝘪𝘨𝘩𝘵𝘴: 𝘉𝘦𝘺𝘰𝘯𝘥 𝘵𝘩𝘦 𝘞𝘦𝘣𝘪𝘯𝘢𝘳

𝗔𝗻𝘁𝗶-𝗖𝗗𝟯𝟴 𝗺𝗔𝗯-𝗯𝗮𝘀𝗲𝗱 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀 𝗮𝗰𝗿𝗼𝘀𝘀 𝘁𝗵𝗲 𝗺𝘆𝗲𝗹𝗼𝗺𝗮 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝘂𝗺

🎙️𝘛𝘶𝘯𝘦 𝘪𝘯𝘵𝘰 𝘢 𝘯𝘦𝘸 𝘱𝘰𝘥𝘤𝘢𝘴𝘵:
https://t.co/0SnLjhunBx

🧑‍💻𝘎𝘢𝘪𝘯 𝘬𝘦𝘺 𝘵𝘢𝘬𝘦𝘢𝘸𝘢𝘺𝘴 𝘧𝘳𝘰𝘮 𝘰𝘶𝘳 𝘐𝘈𝘊𝘏 ��𝘰𝘴𝘵 𝘊𝘰𝘯𝘨𝘳𝘦𝘴𝘴 𝘞𝘦𝘣𝘪𝘯𝘢𝘳:

𝗔𝗻𝘁𝗶-𝗖𝗗𝟯𝟴 𝗺𝗔𝗯-𝗯𝗮𝘀𝗲𝗱 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀 𝗮𝗰𝗿𝗼𝘀𝘀 𝘁𝗵𝗲 𝗺𝘆𝗲𝗹𝗼𝗺𝗮 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝘂𝗺

https://t.co/xLimUES2Ko

@mvmateos @Mohty_EBMT

[IACH @TheIACH]

👂𝘛𝘶𝘯𝘦 𝘪𝘯 𝘵𝘰 𝘵𝘩𝘦 𝘭𝘢𝘵𝘦𝘴𝘵 𝘐𝘈𝘊𝘏 𝘕𝘦𝘸𝘴 𝘱𝘰𝘥𝘤𝘢𝘴𝘵 𝘦𝘯𝘵𝘪𝘵𝘭𝘦𝘥:

𝗙𝗿𝗼𝗺 𝗜𝗠𝗶𝗗𝘀 𝘁𝗼 𝗖𝗘𝗟𝗠𝗼𝗗𝘀: 𝟯𝟬 𝗬𝗲𝗮𝗿𝘀 𝗼𝗳 𝗖𝗲𝗿𝗲𝗯𝗹𝗼𝗻 𝗕𝗶𝗼𝗹𝗼𝗴𝘆 𝗶𝗻 𝗠𝘂𝗹𝘁𝗶𝗽𝗹𝗲 𝗠𝘆𝗲𝗹𝗼𝗺𝗮 
⬇️⬇️
https://t.co/YhPXSbwx1q

𝘊𝘭𝘪𝘤𝘬 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘢𝘣𝘴𝘵𝘳𝘢𝘤𝘵👇
https://t.co/N3haJuxvWq

@Mohty_EBMT @abazarbachi @SLentzsch @ThierryFacon

[IACH @TheIACH]

📰Introducing the IACH Case Report Forum

Every case has a story. Every story has a lesson.
We are delighted to launch the IACH Case Report Forum, a new educational initiative bringing together the global hematology community through real-world clinical cases, expert insights, and interactive discussions.

Most episodes will be inspired by cases published in our journal, Clinical Hematology International: Case Reports, bringing these publications to life and transforming individual clinical experiences into shared knowledge.
From unusual presentations to diagnostic dilemmas and unexpected treatment outcomes, our goal is to stimulate clinical reasoning and translate real-world experiences into practical learning.

Real cases. Real challenges. Expert insights. Global learning.

🎬 Watch our launch announcement and discover what’s coming!

⬇️Visit the CHI: Case Reports Journal
https://t.co/VHjYarVLMR

@Mohty_EBMT

[COMy @COMyCongress]

Registration is open for the 13th COMy Congress!

• May 13-16, 2027
• Paris, France + Online

The biggest questions in myeloma, discussed live.

Register on-site at the early bird rate ⬎ https://t.co/bcLyMoLo90

@Mohty_EBMT

[IACH @TheIACH]

🏥 Can bispecific therapy be delivered safely in the outpatient setting?

As treatment moves beyond clinical trials and into routine practice, managing CRS, ICANS and infection risk becomes critical.
What does safe outpatient administration look like — and how can we minimize treatment interruptions?

Join Elena Zamagni for a practical look at delivering bispecifics safely.

📅 December 11, 2026 | 07:00–10:00AM CT
📍 Great Hall A-D | In person + virtual

👉 Register today: https://t.co/LQCvMSKGcx

@ElenaZamagni @Mohty_EBMT

#MultipleMyeloma #IACH #Hematology

[IACH @TheIACH]

📢𝗪𝗲 𝗮𝗿𝗲 𝗟𝗜𝗩𝗘

𝗧𝗵𝗲 𝗜𝗺𝗽𝗮𝗰𝘁 𝗼𝗳 𝗣𝘀𝘆𝗰𝗵𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗙𝗮𝗰𝘁𝗼𝗿𝘀 𝗼𝗻 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗳𝗼𝗿 𝗠𝘆𝗲𝗹𝗼𝗺𝗮

with William Kenneth Casler

Join the webinar →
https://t.co/nA5Ly9AlwR

@Mohty_EBMT

[IACH @TheIACH]

Happening TODAY!

𝗧𝗵𝗲 𝗜𝗺𝗽𝗮𝗰𝘁 𝗼𝗳 𝗣𝘀𝘆𝗰𝗵𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗙𝗮𝗰𝘁𝗼𝗿𝘀 𝗼𝗻 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗳𝗼𝗿 𝗠𝘆𝗲𝗹𝗼𝗺𝗮

with William Kenneth Casler

6 pm CET • 12 pm NY

Register now for free👇 https://t.co/nA5Ly9zNHj

@Mohty_EBMT